{"protocolSection": {"identificationModule": {"nctId": "NCT00595114", "orgStudyIdInfo": {"id": "1421"}, "secondaryIdInfos": [{"id": "R01HL090927", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/R01HL090927"}, {"id": "HL090927"}], "organization": {"fullName": "Brigham and Women's Hospital", "class": "OTHER"}, "briefTitle": "Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease", "officialTitle": "Ancillary Study of Oxidative Stress and Anti-Inflammatory Lipids in Airway Disease in the MIA (ACRN) and LEUKO (CCRN) Trials"}, "statusModule": {"statusVerifiedDate": "2016-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-12"}, "primaryCompletionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-01-07", "studyFirstSubmitQcDate": "2008-01-07", "studyFirstPostDateStruct": {"date": "2008-01-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2016-05-23", "resultsFirstSubmitQcDate": "2016-05-26", "resultsFirstPostDateStruct": {"date": "2016-07-06", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-09-04", "lastUpdatePostDateStruct": {"date": "2016-10-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Bruce D. Levy", "investigatorTitle": "Principal Investigator", "investigatorAffiliation": "Brigham and Women's Hospital"}, "leadSponsor": {"name": "Brigham and Women's Hospital", "class": "OTHER"}, "collaborators": [{"name": "National Heart, Lung, and Blood Institute (NHLBI)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "Chronic obstructive pulmonary disease (COPD) and asthma are common respiratory diseases in which people experience long-term inflammation of the lungs. Exacerbations, or prolonged worsening of symptoms, of asthma and COPD are often life-threatening and can lead to frequent need for hospitalization. Even with the proper use of bronchodilators, corticosteroids, and other currently available medications, clinical responses among people with COPD and asthma are variable. There remains a significant unmet clinical need for new therapeutic approaches and insights, including the identification of biomarkers to accurately assess the presence of airway infection and intensity of airway inflammation. This study will investigate potential natural biological causes and new biomarkers for increased susceptibility to persistent airway infection in asthma and COPD.", "detailedDescription": "COPD and asthma are chronic lung diseases that result in impaired air flow in the lungs, often causing coughing, wheezing, and shortness of breath. In uncontrolled COPD and asthma, people may experience a rapid worsening of symptoms, which may include fever, difficulty breathing, and chest pain. These exacerbations are the most serious expression of asthma and COPD and are usually caused by lung infections or air allergens. However, the biological basis for susceptibility to airway infection and inflammation is not well understood. Increased oxidative stress within the airways has been linked to several airway diseases. This increase in oxidative stress may reduce production of key fatty acid anti-inflammatory mediators. In turn, this may disrupt the airway's natural immune response mechanisms, making the airways more vulnerable to infection or inflammation during COPD and asthma exacerbations. This ancillary study will determine whether susceptibility to persistent airway infection in asthma and COPD stems from increased oxidative stress that impairs the natural formation of protective fatty acid mediators.\n\nThis ancillary study will use data biological samples, including blood and sputum, from participants currently enrolled in the Macrolides in Asthma (MIA; NCT00318708) and the Antileukotriene Therapy for COPD Exacerbations (KIA; NCT01097694). Biological samples will undergo fatty acid mediator analysis and RNA isolation. There will be no study visits for this study."}, "conditionsModule": {"conditions": ["Asthma", "Pulmonary Disease, Chronic Obstructive"], "keywords": ["COPD", "Airway", "Inflammation", "Infection", "Lipid Mediators", "Oxidative Stress"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"observationalModel": "COHORT", "timePerspective": "RETROSPECTIVE"}, "bioSpec": {"retention": "SAMPLES_WITH_DNA", "description": "Blood and sputum samples with DNA"}, "enrollmentInfo": {"count": 43, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MIA 1", "description": "Participants from the MIA trial who are polymerase chain reaction (PCR) negative and have received treatment with placebo"}, {"label": "MIA 2", "description": "Participants from the MIA trial who are PCR negative and have received treatment with the antibiotic clarithromycin"}, {"label": "MIA 3", "description": "Participants from the MIA trial who are PCR positive and have received treatment with placebo"}, {"label": "MIA 4", "description": "Participants from the MIA trial who are PCR positive and have received treatment with the antibiotic clarithromycin"}, {"label": "LEUKO 1", "description": "Participants from the LEUKO trial who have received treatment with placebo"}, {"label": "LEUKO 2", "description": "Participants from the LEUKO trial who have received treatment with zileuton"}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma", "description": "8-isoprostane levels in sputum", "timeFrame": "Measured at completion of sample analysis"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* No change from the MIA and LEUKO trials\n\nExclusion Criteria:\n\n* No change from the MIA and LEUKO trials", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "This ancillary study will use data and specimens previously collected in the Macrolides in Asthma (MIA) and the Antileukotriene Therapy for COPD Exacerbations (LEUKO) trials.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bruce D. Levy, MD", "affiliation": "Brigham and Women's Hospital", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Brigham and Women's Hospital", "city": "Boston", "state": "Massachusetts", "zip": "02115", "country": "United States", "geoPoint": {"lat": 42.35843, "lon": -71.05977}}]}, "referencesModule": {"references": [{"pmid": "25162465", "type": "DERIVED", "citation": "Ono E, Dutile S, Kazani S, Wechsler ME, Yang J, Hammock BD, Douda DN, Tabet Y, Khaddaj-Mallat R, Sirois M, Sirois C, Rizcallah E, Rousseau E, Martin R, Sutherland ER, Castro M, Jarjour NN, Israel E, Levy BD; National Heart, Lung, and Blood Institute's Asthma Clinical Research Network. Lipoxin generation is related to soluble epoxide hydrolase activity in severe asthma. Am J Respir Crit Care Med. 2014 Oct 15;190(8):886-97. doi: 10.1164/rccm.201403-0544OC."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "MIA 1", "description": "Participants from the MIA trial with mild asthma"}, {"id": "FG001", "title": "KIA 1", "description": "Participants from the KIA trial with severe asthma"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "19"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "19"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "MIA 1", "description": "Participants from the MIA trial with mild asthma"}, {"id": "BG001", "title": "KIA 1", "description": "Participants from the KIA trial with severe asthma"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "43"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "37", "spread": "10"}, {"groupId": "BG001", "value": "40", "spread": "11"}, {"groupId": "BG002", "value": "38", "spread": "10"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "26"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "17"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "8"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "19"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "35"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "23"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "20"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "43"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma", "description": "8-isoprostane levels in sputum", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "pg/ml", "timeFrame": "Measured at completion of sample analysis", "groups": [{"id": "OG000", "title": "MIA 1", "description": "Participants from the MIA trial with mild asthma"}, {"id": "OG001", "title": "KIA 1", "description": "Participants from the KIA trial with severe asthma"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "19"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "292.4", "spread": "51.0"}, {"groupId": "OG001", "value": "421.8", "spread": "195.4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "MIA 1", "description": "Participants from the MIA trial with mild asthma", "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 0, "otherNumAtRisk": 24}, {"id": "EG001", "title": "KIA 1", "description": "Participants from the KIA trial with severe asthma", "seriousNumAffected": 0, "seriousNumAtRisk": 19, "otherNumAffected": 0, "otherNumAtRisk": 19}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Bruce D. Levy", "organization": "Brigham and Women's Hospital", "email": "blevy@partners.org", "phone": "617-525-5407"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000029424", "term": "Pulmonary Disease, Chronic Obstructive"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}, {"id": "D000002908", "term": "Chronic Disease"}, {"id": "D000020969", "term": "Disease Attributes"}, {"id": "D000010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M10293", "name": "Inflammation", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "asFound": "Pulmonary Disease", "relevance": "HIGH"}, {"id": "M10283", "name": "Infections", "relevance": "LOW"}, {"id": "M6368", "name": "Communicable Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M23449", "name": "Pulmonary Disease, Chronic Obstructive", "asFound": "Pulmonary Disease, Chronic Obstructive", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "M6147", "name": "Chronic Disease", "relevance": "LOW"}, {"id": "M22700", "name": "Disease Attributes", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "BC01", "name": "Infections"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M4222", "name": "Anti-Bacterial Agents", "relevance": "LOW"}, {"id": "M4224", "name": "Antibiotics, Antitubercular", "relevance": "LOW"}, {"id": "M19585", "name": "Clarithromycin", "relevance": "LOW"}, {"id": "M245553", "name": "Zileuton", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}, {"abbrev": "ARhu", "name": "Antirheumatic Agents"}, {"abbrev": "Analg", "name": "Analgesics"}]}}, "hasResults": true}